Abstracts tagged "corticosteroids"

Abstract Number: 1051 • ACR Convergence 2024
Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis
Daniel Labson¹, Qian Cai², Concetta Crivera³ and Federico Zazzetti⁴, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Raritan, NJ, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Titusville, NJ, ³Janssen Global Services, LLC, a Johnson & Johnson Company, Immunology Market Access, Horsham, PA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune conditions primarily characterized by muscle weakness and inflammation. Real-world evidence on economic outcomes of patients with…
Abstract Number: 2438 • ACR Convergence 2024
Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus
Vasileios Kyttaris¹, Gelareh Atefi², Dan Persons³, Dana Withrow³ and Mawuena Binka⁴, ¹BIDMC, Boston, MA, ²AstraZeneca, Media, PA, ³Trio Health, Louisville, CO, USA, Louisville, ⁴BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE
Background/Purpose: Oral corticosteroids (OCS) are a mainstay in the clinical management of systemic lupus erythematosus (SLE). However, prolonged use may result in systemic side effects.1…
Abstract Number: 1186 • ACR Convergence 2024
Intra-articular Corticosteroid Injections for Knee Osteoarthritis: Does the Dose Matter?
Neenu Sukumaran¹ and John Waterman², ¹University of Connecticut, Avon, CT, ²Veterans Administration, Simsbury, CT
Background/Purpose: Intra-articular(IA) corticosteroid injections for knee osteoarthritis (OA) have been performed for over 60 years. However, the appropriate dose of IA corticosteroids has not been determined. To…
Abstract Number: 2503 • ACR Convergence 2024
Hypothalamic-Pituitary-Adrenal Axis Suppression by Prednisolone Reversed by the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Clofutriben
Frank S Czerwiec¹, Irina Bancos², Paul M Stewart³, Ketan Desai¹ and David A Katz¹, ¹Sparrow Pharmaceuticals, Portland, OR, ²Mayo Clinic, Rochester, MN, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Approximately 1% of the population rely on chronic glucocorticoid (GC) prescription to control autoimmune and inflammatory conditions. Risk of GC induced adrenal insufficiency (GC-AI)…
Abstract Number: 1193 • ACR Convergence 2024
Ultrasound-Guided Corticosteroid Injection versus Iontophoresis in Rhizarthrosis: A Prospective Comparative Multicentric Study
Olga Rusinovich¹, Andrea Liso Andrino², Maria Concepcion Sanchez³, Pilar Navarro Alonso⁴, Miguel Cantalejo Moreira⁵, ALBERTO DIAZ OCA⁴, Pablo Navarro Palomo⁶, Maria Machattou⁷, Maria Alonso de Francisco³, Carlota Navarro Joven⁸, Alejandro Martinez Rodado³, laura Ramos Ortiz de Zarate⁹, hildegarda Godoy Tundidor¹⁰, Maria Carmen Barbadillo Mateos⁷, Blanca Garcia-Magallon⁷, Jose Campos⁷, Mónica Fernández Castro¹¹, JESUS SANZ SANZ⁶ and Jose Luis Andreu⁶, ¹Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ²Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Madrid, Spain, ³Puerta de Hierro Majadahonda University Hospital, Majadahonda, Spain, ⁴Fuenlabrada University Hospital, Fuenlabrada, Spain, ⁵Hospital Universitario de Fuenlabrada, Fuenlabrada. Madrid, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, ⁷Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ⁹Puerta de Hierro Majadahonda University Hospital, Majahonda, Spain, ¹⁰Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain
Background/Purpose: Trapeziometacarpal osteoarthritis is a common degenerative disease that causes pain and thumb dysfunction. It affects 16-25% of the population, mainly middle-aged women. Treatment modalities…
Abstract Number: 2679 • ACR Convergence 2024
Predictors of Fracture in SLE: A Longitudinal Cohort Study
Kristen Chao¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Fractures are one of the most common damage items in the SLICC/ACR Damage Index. Although commonly attributed to corticosteroid use, the complexity of ways…
Abstract Number: 1243 • ACR Convergence 2024
A Patient-Focused Program for Using Steroids Wisely
John Stone¹, Michelle Petri², Jeffrey Gelfand³, Camille Kotton⁴, Jane McDowell⁵, George Papaliodis⁶, meredith Marinaro⁷, Matt Wilkinson⁸, Walter Lentfert⁹ and Martha Stone¹⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of California, San Francisco, San Francisco, CA, ⁴Harvard Medical School, Boston, MA, ⁵Queens University Belfast, Belfast, Ireland, ⁶Massachusetts General Hospital, Boston, MA, ⁷Novartis, Hartford, CT, ⁸UpThereEverywhere, London, United Kingdom, ⁹UpThereEverywhere, Wilmington, NC, ¹⁰Steritas, LLC, CONCORD, MA
Background/Purpose: Patients have no comprehensive, curated resource on steroid use to facilitate effective collaboration in their own care. Consequently, truly shared decision making around steroid…
Abstract Number: 1495 • ACR Convergence 2024
Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
Mawuena Binka¹, Rana Muhammad Qasim Khan², Joseph Tkacz³, Donna McMorrow³, Laurence Gozalo³ and Gail Kerr⁴, ¹BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, ³Inovalon, Bowie, MD, ⁴Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
Abstract Number: 1511 • ACR Convergence 2024
Lupus Nephritis and Response to Treatment in Latin America
Rosana Quintana¹, Romina Nieto², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Marina Scolnik⁸, Carmen Funes Soaje⁹, Paula Alba¹⁰, Veronica Saurit¹¹, Mercedes Garcia¹², Guillermo Berbotto¹³, VERONICA BELLOMIO¹⁴, Wilfredo Patiño Grageda¹⁵, Graciela Gómez¹⁶, Cecilia Pisoni¹⁷, Ana Malvar¹⁸, Vicente Juarez¹⁹, Nilzio A. Da Silva²⁰, ODIRLEI MONTICIELO²¹, Henrique Ataide Mariz²², Francinne Machado Ribeiro²³, Eduardo Borba²⁴, Luciana Parente²⁴, Edgard Torres²⁵, Oscar Neira²⁶, Loreto Massardo²⁷, Gustavo Aroca Martínez²⁸, Carlos A. Cañas Davila²⁹, Gerardo Quintana López³⁰, Carlos Enrique Toro-Gutierrez³¹, Mario Moreno³², Andres Zuñiga³³, Miguel Angel Saavedra Salinas³⁴, Margarita Portela Hernandez³⁵, Hilda Fragoso-Loyo³⁶, Luis H. Silveira Torre³⁷, Ignacio García De La Torre³⁸, Carlos Abud Mendoza³⁹, Marcos Fonseca Hernández⁴⁰, Jorge Esquivel-Valerio⁴¹, Isabel Acosta Colman⁴², Jhonatan Losanto⁴³, Claudia Selene Mora Trujillo⁴⁴, Katiuzka Zuñiga Corrales⁴⁵, Roberto Muñoz Louis⁴⁶, Martin Rebella⁴⁷, Álvaro Danza⁴⁸ Manuel Ugarte-Gil⁴⁹, Graciela Alarcon⁵⁰, Urbano Sbarigia⁵¹, Federico Zazzetti⁵², Ashley Orillion⁵³, Guillermo Pons-Estel⁵⁴ and Bernardo Pons-Estel⁵⁴, ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Hospital Italiano, Cordoba, Argentina, ¹⁰Hospital Cordoba, Cordoba, Spain, ¹¹hospital privado universitario de cordoba, Córdoba, Argentina, ¹²HIGA San Martin, La Plata, Argentina, ¹³Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, ROSARIO, Argentina, ¹⁴Hospital Padilla, San Miguel de Tucumán, Argentina, ¹⁵Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹⁶Instituto de Investigaciones Médicas Alfredo Lanari, Autónoma de Buenos Aires, Argentina, ¹⁷CEMIC, Buenos Aires, Argentina, ¹⁸Organización Médica de Investigación, Buenos Aires, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Salta, Argentina, ²⁰Hospital das Clinicas, Universidad Federal de Goias, Goias, Goias, Brazil, ²¹HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ²²Universidad Federal de Pernambuco, Pernambuco, Brazil, ²³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁵Universidad Federal São Paulo, São Paulo, SP, Brazil, ²⁶Hospital del Salvador, Santiago de Chile, Chile, ²⁷Facultad de Medicina y Ciencia, Universidad San Sebastián, San Sebastián, Chile, ²⁸Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ³⁰Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ³¹Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, ³²Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ³⁵Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³⁷Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ³⁸Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, ⁴⁰Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico, ⁴¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital de Clínicas I, San Lorenzo, Paraguay, ⁴⁴Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴⁵Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ⁴⁶Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, ⁴⁷Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ⁴⁸Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, ⁴⁹Universidad Cientifica del Sur, Lima, Lima, Peru, ⁵⁰The University of Alabama at Birmingham, Birmingham, AL, ⁵¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵²Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵³Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ⁵⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
Abstract Number: 0168 • ACR Convergence 2024
Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database
Tatsuya Atsumi¹, Hironari Hanaoka², Nobuo Nishijima³, Kohji Murakami⁴, Mariko Nio³, Tsutomu Urakawa³, Takaaki Fujimura³ and Hiroki Hayashi⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁴Nippon Shinyaku Co., Ltd., Tokyo, Japan, ⁵Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Background/Purpose: Lupus nephritis (LN) is one of the most frequent organ manifestations of systemic lupus erythematosus (SLE), affecting morbidity and mortality in SLE. LN is…
Abstract Number: 1530 • ACR Convergence 2024
Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant
Maral DerSarkissian¹, Yan Chen¹, Brendan Rabideau¹, Theo Man¹, Karen Worley², Bernard Rubin³, Karen Costenbader⁴ and S. Sam Lim⁵, ¹Analysis Group, Los Angeles, CA, ²GSK, Collegeville, PA, ³GSK, Durham, NC, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁵Emory University, Atlanta, GA

Background/Purpose: Early diagnosis and treatment of SLE improves prognosis and quality of life.1 Belimumab (BEL), a human immunoglobulin G1λ (IgG1λ) mAb that selectively binds to…
Abstract Number: 0535 • ACR Convergence 2024
Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients
Pauline Bovens¹, Luuk Van Esveld², Maike Wientjes¹, Noortje van Herwaarden³, David Ten Cate⁴, Eward Melis³, Nienke Lesuis⁵, Bart van den Bemt⁶ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Utrecht, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Sint Maartenskliniek, Rotterdam, Netherlands, ⁵Hospital Group Twente, Almelo, Netherlands, ⁶Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: It has been demonstrated that pretreatment with intravenous glucocorticoids can prevent infusion-related reactions (IRR) that may occur in RA patients receiving rituximab infusions [1].…
Abstract Number: 1593 • ACR Convergence 2024
Efficacy of Increasing the Dose of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis
Federica Pallotti¹, Philippe Bonniaud², Perrine SMETS³, stephanie Habib⁴, Amandine Perier⁵, Alban Deroux⁶, Julie Mankikian⁷, Antoine Neel⁸, Clémentine Rousselin⁹, Raphaele Seror¹⁰, Camille Taille¹¹, Etienne Crickx¹², Candice La Croix¹³, Philippe Blanche¹⁴, Loïc Guillevin¹⁵, Xavier Puéchal¹⁶ and Benjamin Terrier¹⁷, and French Vasculitis Study Group, ¹Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, ²Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ³Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁴Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, ⁵CH de Niort, Niort, France, ⁶Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ⁷CHRU Tours, Service de Pneumologie et d'Explorations Fonctionnelles Respiratoires, Tours, France, ⁸Department of Internal Medicine, CHU Nantes, Nantes, France, ⁹Service de médecine interne et néphrologie, centre hospitalier de Valenciennes, Valenciennes, France, ¹⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ¹¹Bichat Hospital, Paris, France, ¹²Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, APHP, Paris, France, ¹³Department of Otolaryngology, Hôpital Cochin, APHP, Paris, France, ¹⁴Department of Internal Medicine, National Referrence Center for Systemic and Autoimmune Diseases, Hôpital Cochin, APHP, Paris, France, ¹⁵National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ¹⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) patients frequently develop glucocorticoid (GC)-dependent asthma and/or ENT manifestations, leading to long-term GC requirement and side effects. Mepolizumab, an…
Abstract Number: 0667 • ACR Convergence 2024
Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry
Takehiro HIrayama¹, Kohei Tsujimoto², Kayoko Kaneko³, Sakiko Isojima⁴, Kunihiro Ichinose⁵, Yasunori Iwata⁶, Kenji Oku⁷, Kenei Sada⁸, Yoshiya Tanaka⁹, Ayako Nakajima¹⁰, Keishi Fujio¹¹, Masakazu Matsushita¹², Takako Miyamae¹³, Atsuko Murashima³ and Atsushi Kumanogoh¹⁴, ¹Osaka university, Ibaraki City, Japan, ²Osaka University, Toyonaka, Osaka, Osaka, Japan, ³National Center for Child Health and Development, Setagaya, Tokyo, Japan, ⁴Showa Univeristy, Shinagawa, Tokyo, Japan, ⁵Shimane University, Izumo, Shimane, Japan, ⁶Kanazawa University, kanazawa, Japan, ⁷Kitazato University, Sagamihara, Kanagawa, Japan, ⁸Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ¹¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., TOKYO, Japan, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴Osaka University, Osaka, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse clinical manifestations and organ involvement, posing significant challenges in its management. The emergence…
Abstract Number: 1697 • ACR Convergence 2024
Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Methotrexate 25mg Per Week for Recently Diagnosed PolyMyalgia Rheumatica
Thomas Bolhuis¹, Noortje Kooijman¹, Diane Marsman¹, Gijs Snijders², Alfons den Broeder³, Nathan den Broeder⁴ and Aatke Van der maas⁵, ¹Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands, Ubbergen, Netherlands, ²Department of Rheumatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands, Gelre, Netherlands, ³Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁵St Maartenskliniek, Ubbergen, Netherlands
Background/Purpose: The most effective treatment for Polymyalgia rheumatica (PMR) are glucocorticoids (GC), but these are associated with toxicity. Three randomized controlled trials (RCTs) suggest methotrexate…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].